Last reviewed · How we verify
NCT04802304
Beyond Bias - Reducing Provider Bias Towards Adolescents to Increase Contraception Take-Up in Tanzania, Burkina Faso, and Pakistan
NA trial testing Beyond Bias Treatment in Family Planning Services in 233 participants. Completed in 14 October 2022.
1 September 2021
Quick facts
| Lead sponsor | RAND |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 233 |
| Start date | 1 September 2020 |
| Primary completion | 1 September 2021 |
| Estimated completion | 14 October 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Beyond Bias Treatment
Conditions studied
- Family Planning Services — all drugs for Family Planning Services →
Sponsor
RAND — full company profile →
Who can join
Under 24, female only, with Family Planning Services. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Beyond Bias will evaluate the impact of an intervention designed to reduce family planning provider bias towards young, unmarried, and nulliparous women in Tanzania, Burkina Faso, and Pakistan. The intervention has three components: 1) a summit that includes impactful stories told to and by family planning providers that highlight the consequences of provider bias, 2) a forum for continued communication between providers, and 3) a rewards program where clinics in which providers exhibit less biased client interactions or who have improved the most towards this end will be rewarded with social recognition and a ceremony. Half of the eligible clinics in each country (233 in total) are randomly assigned to receive the intervention, while the remaining half serves as control. The objective of the evaluation is to estimate the impact of the intervention on a range of outcomes related to quality of family planning care among young, unmarried, and nulliparous women. The investigators hypothesize that the intervention will increase the share of young, unmarried, and nulliparous women who received counseling on a range of methods, counseling on long acting methods, and who received their preferred method. The investigators will collect four types of data to evaluate the intervention: 1) provider surveys, 2) mystery clients' visits, 3) direct observations of client-provider interactions, and 4) qualitative interviews with clients, providers, and implementors.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04802304
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Family Planning Services
Currently open trials in the same condition.
- NCT07008950 — Self-efficacy and Knowledge (SEEK) Trial to Improve Sexual Reproductive Health and Well-being for Syrian Refugee Women a · NA · recruiting
Other RAND trials
Trials by the same sponsor.
- NCT06048328 — Game Changers for Family Planning Peer Advocacy Program · Phase 1, PHASE2 · not yet recruiting
- NCT07072819 — Pilot of Training on 988 and Narcan · NA · completed
- NCT06699251 — Effectiveness of Brief Intervention in Primary Care for Diverse Young People (Chat) · NA · recruiting
- NCT06949774 — INcentives and ReMINDers to Improve Long-term Medication Adherence (INMIND) · NA · recruiting
- NCT06827288 — Adaptive Interventions for Emergency Department Patients With Opioid Use Disorder · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04802304 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by RAND
- Last refreshed: 17 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04802304.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing